Researchers have shown in cells and models that the central nervous system and neurons can become a target of SARS-CoV-2 infection.
List view / Grid view
Filter the results
Scientists show that an antibody targeting a protein acting as a viral toxin, can prevent the dengue virus from infecting human cells.
Inhibiting the ACSS2 enzyme with a molecule called VY-3-135 caused a significant reduction in the growth of breast cancer tumours in vivo.
Researchers have shown rhesus macaques and baboons develop strong signs of acute viral infection from SARS-CoV-2, making them ideal models.
Researchers were able to eradicate breast cancer in mice when they combined CAR T cells with STING pathway agonists and immunotherapeutic antibodies.
Cancer researchers have created a new class of drugs to selectively target and destroy myeloid leukaemia cells with TET gene mutations.
Opaganib reduced blood clot length and weight in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
Using CRISPR-Cas9, scientists have developed a new method for generating mouse lines for vaccine research in just a few weeks.
Scientists report their phage-based inhaled vaccine delivery system elicited a robust antibody response in both mice and non-human primates.
A non-hallucinogenic version of the psychedelic drug ibogaine could treat psychiatric disorders, pre-clinical trials have shown.
A long-term study of macaques given mitochondrial replacement therapy (MRT) found that both treated individuals and their offspring were healthy and developed normally.
Mice treated with a small molecule inhibitor of cadherin 11 (CDH11) had reduced pancreatic cancer growth and increased survival time.
Investigators found that red propolis can kill schistosomes at all stages of development and therefore suggest it could be highly effective for treating schistosomiasis.
Scientists suggest that research using XPSCs, an intermediate form of embryonic stem cell, could help accelerate the development of stem cell-derived tissues and organs for transplantation.
A team has found that their drug Molnupiravir (MK-4482/EIDD-2801) acts as an antiviral against SARS-CoV-2 in pre-clinical studies.